Stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) are increasingly used as initial therapies for brain metastases (BM).We aimed to assess the outcomes of SRS/FSRT in patients aged 65 years who had 1-10 BM from non-small cell lung cancer (NSCLC). Materials and MethodsWe retrospectively reviewed 91 elderly NSCLC patients with 222 BM who were treated with SRS/FSRT at two institutions between 2010 and 2020.The primary endpoint was overall survival (OS) after SRS/FSRT.In addition, in-field local control (IFLC) within the treated field was evaluated.Statistical analysis was performed to identify the prognostic factors affecting OS and IFLC.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: